There are other cancers with a known or suspected role of MdmX overexpression in tumor development or progression, such as, for example, retinoblastoma [5,6], breast carcinoma [7,8], or chronic lymphocytic leukemia (CLL) [9]. This evidence concerns the gene MDM4 and B-cell chronic lymphocytic leukemia.